Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

1198 results about "Patient treatment" patented technology

Inpatient treatment is a type of treatment in which a patient is provided with 24 hour care at a live-in facility. Both psychiatric and physical health assistance are included in this treatment.

Lumen Morphology and Vascular Resistance Measurements Data Collection Systems, Apparatus and Methods

A method and apparatus of automatically locating in an image of a blood vessel the lumen boundary at a position in the vessel and from that measuring the diameter of the vessel. From the diameter of the vessel and estimated blood flow rate, a number of clinically significant physiological parameters are then determined and various user displays of interest generated. One use of these images and parameters is to aid the clinician in the placement of a stent. The system, in one embodiment, uses these measurements to allow the clinician to simulate the placement of a stent and to determine the effect of the placement. In addition, from these patient parameters various patient treatments are then performed.
Owner:LIGHTLAB IMAGING

System and method for improving clinical decisions by aggregating, validating and analysing genetic and phenotypic data

The information management system disclosed enables caregivers to make better decisions, faster, using aggregated genetic and phenotypic data. The system enables the integration, validation and analysis of genetic, phenotypic and clinical data from multiple subjects who may be at distributed facilities. A standardized data model stores a range of patient data in standardized data classes that encompass patient profile information, patient symptomatic information, patient treatment information, and patient diagnostic information including genetic information. Data from other systems is converted into the format of the standardized data classes using a data parser, or cartridge, specifically tailored to the source system. Relationships exist between standardized data classes that are based on expert rules and statistical models. The relationships are used both to validate new data, and to predict phenotypic outcomes based on available data. The prediction may relate to a clinical outcome in response to a proposed intervention by a caregiver. The statistical models may be inhaled into the system from electronic publications that define statistical models and methods for training those models, according to a standardized template. Methods are described for selecting, creating and training the statistical models to operate on genetic, phenotypic and clinical data, in particular for underdetermined data sets that are typical of genetic information. The disclosure also describes how security of the data is maintained by means of a robust security architecture, and robust user authentication such as biometric authentication, combined with application-level and data-level access privileges.
Owner:NATERA

System and method of measuring disease severity of a patient before, during and after treatment

A system and method of obtaining serial biochemical, anatomical or physiological in vivo measurements of disease from one or more medical images of a patient before, during and after treatment, and measuring extent and severity of the disease is provided. First anatomical and functional image data sets are acquired, and form a first co-registered composite image data set. At least a volume of interest (ROI) within the first co-registered composite image data set is identified. The first co-registered composite image data set including the ROI is qualitatively and quantitatively analyzed to determine extent and severity of the disease. Second anatomical and functional image data sets are acquired, and form a second co-registered composite image data set. A global, rigid registration is performed on the first and second anatomical image data sets, such that the first and second functional image data sets are also globally registered. At least a ROI within the globally registered image data set using the identified ROI within the first co-registered composite image data set is identified. A local, non-rigid registration is performed on the ROI within the first co-registered composite image data set and the ROI within the globally registered image data set, thereby producing a first co-registered serial image data set. The first co-registered serial image data set including the ROIs is qualitatively and quantitatively analyzed to determine severity of the disease and/or response to treatment of the patient.
Owner:SIEMENS MEDICAL SOLUTIONS USA INC

Task and Workflow Management System for Healthcare and other Applications

A task management system uses patient tags (e.g., wireless RFID, Infrared tracking, GPS etc.) for patient location tracking, together with an integrated workflow system to automatically, track patient location how long they have been there and how many patients are at the same location (e.g., waiting room) and manages waiting time and an overall waiting queue, supporting automated adjustment of healthcare staffing, patient flows, and team coordination. A task management system for use in providing healthcare to a patient includes a patient tracking processor and a workflow processor. The patient tracking processor automatically acquires data derived by wireless communication from patient attached tag devices for use in identifying a location of multiple patients in a healthcare enterprise and identifying a first number of patients at a particular location and a second number of patients awaiting receiving a particular type of treatment. The workflow processor automatically initiates a patient load balancing activity to improve a match between a healthcare resource and a patient load by communicating a message to update a healthcare worker task schedule with a task in response to a determination the identified first or second number of patients exceeds a predetermined threshold number.
Owner:SIEMENS AG

Non-invasive neuro stimulation system

A device (10, 50, 60, 70, 80, 90) is used to apply an electric pulse or spike to a patient to treat the patient. The device can have a series of preset treatments programmed therein. A user can select a treatment from menus displayed on a display (100). The impedance of the skin and underlying tissue to be treated can be measured prior to the treatment to locate active areas on the skin for treatment. The impedance measurement can be made at a sufficiently low level to avoid treatment of the patient that could cause a change in the impedance. A phase detector can be used to isolate the capacitance value in the impedance. The charge delivered to the patient can be measured and the device can adjust the charge as the skin impedance varies during treatment to deliver uniform charges to the skin. A variety of probes can be used with the device, with the device automatically detecting the type of probe attached. Multiple electrodes can be used on the probe, which allows the active areas in contact with the probe to be identified prior to treatment to allow the treatment to concentrate on the active areas.
Owner:HTK ENTERPRISES INC

Integrated patient bed system

The present invention includes an integrated system and methods for patient treatment, the system includes a hospital bed; a plurality of patient diagnostic and treatment devices connected to a network, wherein each of the devices can communicate to a network and exchange information with the network about the care of a patient; and a processor accessible adjacent to the bed and connected to the network to integrate information obtained from the devices through the network with one or more additional sources of information databases, wherein the processor can communicate to one or more patient treatment devices either directly or via the network and the processor directs the one or more patient treatment devices to change the treatment of the patient.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions

Patients inflicted with various clustering chronic diseases require treatment with multiple drugs having distinct mechanisms of action. Accordingly, patients with multiple conditions suffer from cumulative side effects of multiple drugs as well as drug-drug interactions. Embodiments, agents, compounds or drugs of the present invention, such as sesquiterpenes, e.g., Zerumbone, replace an equal or larger number of approved drugs during patient treatment. Examples of disorders prevented or ameliorated by administration of the formulations of this invention include but are not limited to inflammatory diseases that may be, oncological, genetic, ischemic, infectious, neurological, hematological, ophthalmological, rheumatoid, orthopedic, neurological, hematological, kidney, vascular, dermatological, gynecological, or obstetric. The present invention further relates to a method of identifying agents, compounds or drugs useful in preventing or treating CDCP related diseases and conditions as well as other disorders, diseases and conditions treatable or preventable by the same agents, compounds or drugs.
Owner:REID CHRISTOPHER BRIAN

Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA

InactiveUS20090105173A1Increased riskPrevent ototoxicitySugar derivativesGenetic material ingredientsDiseaseEprotirome
The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from acute renal failure or other kidney diseases comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient.
Owner:QUARK FARMACUITIKALS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products